New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir).
The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance and symptom control at end of week 8, and maintained through week 16. No new safety signals were identified and maribavir was associated with lower incidence of neutropenia compared to IAT. Takeda plans to submit the SOLSTICE data for presentation at an upcoming scientific meeting.1
“Achieving the primary endpoint of the SOLSTICE trial is an exciting new development in the search for a treatment for transplant recipients with refractory/resistant CMV infection. Today, transplant patients who do not respond or experience adverse events related to existing therapies may be at higher risk for complications from the virus, including transplant failure and death. Maribavir has the potential to redefine management of post-transplant CMV infections by helping patients clear the virus with less treatment limiting toxicities,” said Obi Umeh, MD, Vice President and Maribavir Global Program Leader, Takeda. “We look forward to discussing these data with global health authorities including the U.S. Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”
CMV is a beta herpesvirus that commonly infects humans; serologic evidence of prior infection can be found in 40-100% of various adult populations.2 However, serious disease may occur in individuals with compromised immune systems, which includes patients who received immunosuppressants associated with various types of transplants including hematopoietic stem cell transplants (HSCT) or solid organ transplants (SOT).3 CMV is a ubiquitous virus that typically resides latent and asymptomatic in the body but reactivates during periods of immunosuppression.3,4 Out of the estimated 200,000 adult transplants per year, CMV is one of the most common viral infections experienced by transplant recipients, with an estimated incidence rate of around 8-75% in SOT recipients and 5-30% in HSCT recipients.4-8
In transplant recipients, reactivation of CMV can lead to serious consequences including loss of the transplanted organ and, in extreme cases, can be fatal.9,10 Existing therapies to treat post-transplant CMV infections may demonstrate toxicities that require dose-adjustments, need hospitalization for administration, or may fail to adequately suppress viral replication.11-13
Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. Maribavir is an investigational treatment that has not been approved for use by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or any other regulatory authorities.
Maribavir has been granted Orphan Drug Designation by the European Commission as a treatment of CMV disease in patients with impaired cell mediated immunity and by the FDA for treatment of clinically significant CMV viremia and disease in at-risk patients. Orphan status is granted to certain investigational medicines intended for the treatment or prevention of a rare, life-threatening disease. The FDA has also granted maribavir Breakthrough Therapy Designation as a treatment for CMV infection and disease in transplant patients resistant or refractory to prior therapy. Breakthrough Therapy Designation expedites the development and review of investigational treatments for serious conditions with preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over available therapy. These designations do not guarantee that the EMA or FDA will approve maribavir for the treatment of CMV infections in transplant patients, and the timing of any such approval is uncertain.
About Takeda’s Maribavir Phase 2 Study
In the Phase 2 study in HSCT and SOT recipients with CMV infections refractory or resistant to ≥1 existing anti-CMV antiviral agents (valganciclovir, ganciclovir, or foscarnet), dysgeusia described as metallic or bitter tastes was the most common adverse event, followed by nausea, vomiting and diarrhea. Neutropenia was reported in 11% and renal impairment in 16% of patients.14
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
1 VV-MED-9909_Takeda DOF. TAK-620 303 Memorandum. November 2020.
2 Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull WHO. 1973;49:103-6.
3 De la Hoz, RE., et al. Diagnosis and treatment approaches to CMV infections in adult patients. J Clin Virol. 2002;S1-S12.
4 Azevedo LS, Pierrotti LC, Abdala E, et al. Cytomegalovirus infection in transplant recipients. Clinics. 2015;70(7):515-523.
5 World Health Organization. International Report on Organ Donation and Transplantation Activities. 2018. Accessed December 2, 2020. Available at: http://www.transplant-observatory.org/wp-content/uploads/2020/10/glorep2018-2.pdf.
6 World Health Organization. Haematopoietic Stem Cell Transplantation HSCtx. Accessed on December 2, 2020. Available at: https://www.who.int/transplantation/hsctx/en/.
7 Razonable RR, Eid AJ. Viral infections in transplant recipients. Minerva Med. 2009 Dec; 100(6):479-501.
8 VV-MED-9910_Takeda DOF. Epidemiology of cytomegalovirus in solid organ transplant and hematopoietic stem cell transplant patients. February 2018.
9 Fishman JA. Infection in organ transplantation. American Journal of Transplantation. 2017;17:856-879.
10 Kenyon, Michelle, and Aleksandra Babic, editors. The European Blood and Marrow Transplantation Textbook for Nurses: under the Auspices of EBMT. Springer Open, 2018.
11 Martín-Gandul C, Pérez-Romero P, González-Roncero FM, et al. Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients. J Infect. 2014; 69: 500-6.
12 Chemaly RF, Chou S, Einsele H, et al. Clinical Infectious Diseases. 2019;68(8):1420-1426.
13 Beyer K, Abboud M, Hambright K, et al. Biol Blood Marrow Transplant. 2017;S175 (220).
14 Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infec Dis. 2019;68(8):1255-1264.
+81 (0) 3-3278-2095
Media Outside Japan
+1 617 301 2092
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Launches New Mobile Game Commerce Solution to Help Developers Expand Their Mobile Business26.1.2021 18:01:00 EET | Press release
Xsolla, the video game commerce company powered by Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, today launched its Mobile Game Commerce solution designed to level up and manage mobile games beyond the app stores. Xsolla’s new innovative Mobile Game Commerce solution enables developers to streamline user acquisition, create better ways for players to discover games, simplify the online game commerce experience, build an online player community, expand their global footprint and increase future transaction revenue. Mobile Game Commerce gives developers the tools to successfully operate PC and online versions of their mobile games, and create top-up experiences for players to add virtual currencies to their accounts: Expand onto PC and Online to unlock additional distribution, acquisition and in-game monetization channels for new and existing players. Communicate, better serve and share new offerings with
Andersen Global Expands Coverage in South Africa26.1.2021 17:30:00 EET | Press release
Andersen Global enhances its presence in South Africa through a Collaboration Agreement with full-service accounting and tax consulting firm SAB&T Business Consulting (SAB&T), expanding the organization’s coverage to nine additional cities in the country: Centurion, Bloemfontein, Cape Town, Durban, Kimberley, Nelspruit, Polokwane, Port Elizabeth and Rustenburg. Founded in 1994, SAB&T’s team of professionals serves individuals, SMEs and multinationals in various industries including agriculture, education, entertainment, hospitality, manufacturing, retail and technology. “Our firm has developed strong relationships with our clients by providing best-in-class solutions and maintaining the highest standards of professional conduct and expertise since the birth of South Africa’s democracy in 1994,” Chief Operating Officer Fazel Sulaman said. “Our goal is to remain a leading firm by continuing to meet and exceed clients’ expectations. We look forward to working with Andersen Global’s member
Moody’s Analytics CECL Solutions Complete 2020 SOC 1® Examinations26.1.2021 17:00:00 EET | Press release
Moody’s Analytics today announced that the ImpairmentStudio™, RiskCalc™, and CMM™ platforms have completed System and Organization Controls (SOC 1) Type 2 examinations under the attestation standards established by the American Institute of Certified Public Accountants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005350/en/ The SOC 1 report examination encompasses policies, operating procedures, and controls related to financial reporting of user entities by an independent auditor, to objectively validate that the service organization meets its declared control objectives. Banks, credit unions, and insurance companies use our ImpairmentStudio solution to automate allowance calculations, analysis, reporting, and workflow. This award-winning solution combines our credit risk data, best-in-class analytics, and impairment accounting expertise, and has been celebrated for its completeness and broad CECL automation capabi
Brightcove Receives Two Technology and Engineering Emmy® Awards26.1.2021 17:00:00 EET | Press release
Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, today announced it is the recipient of two Technology and Engineering Emmy® Awards, awarded by the National Academy of Television Arts & Sciences (NATAS) for excellence in engineering innovation. The recent accolades further solidify Brightcove’s leadership within the industry, most notably as one of the only online video platforms to be recognized for its distinguished video services. Brightcove’s Context Aware Encoding technology was recognized for excellence and engineering creativity in the Development of Perceptual Metrics for Video Encoding Optimization category. The technology enables customers to distribute videos encoded at high visual quality while minimizing network bandwidth and storage costs. Additionally, Brightcove’s Zencoder and Video Cloud products were acknowledged in the Development of Massive Processing Optimized Compression Technologies category. The award distinguishes Brightcove's innovation
PROFIL® Launches New Website26.1.2021 17:00:00 EET | Press release
PROFIL®, a PennEngineering® company and leading global manufacturer of mechanically attached fasteners for the automotive market, has announced the launch of a new website, www.profil-global.com . The new website, available in English and German, provides visitors with an enhanced user experience that makes it easy to learn about PROFIL® products, installation methods, and application usage. In addition to its highly intuitive and modern site design, new content features include: Interactive Search – users can search for and filter product information by a variety of features including product type, size, material, application, and fastening method. Cost Calculator – new cost calculator tool determines the potential cost savings gained by using PROFIL® In-Die Mechanically Attached Fasteners (MAF) compared to weld fasteners. Interactive Application Overview – through an animated and interactive vehicle diagram, users can see exactly how and where PROFIL® fasteners are used by applicatio
Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis26.1.2021 16:00:00 EET | Press release
Mundipharma and Cidara Therapeutics today announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rezafungin, a novel, once-weekly echinocandin, for the treatment of invasive candidiasis (IC).4 The EMA considers ODD status for medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than five per 10,000 people in the EU.5 It is estimated that IC occurs in around 0.84 per 10,000 people in the EU,6 and mostly affects hospitalised, immunocompromised or critically ill patients.2 IC continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, mortality rates are as high as 40%.3 IC is characterised as a severe, life-threatening systemic Candida infection of the bloods
Software Industry: Nexway™ Reinforces the Customer Experience Capabilities of its Monetize Personalized Growth Platform26.1.2021 16:00:00 EET | Press release
Nexway, a leading software and service company for e-commerce and payments, is very excited to launch the latest features on its personalized growth platform Nexway Monetize, moving forward in its mission to expand the online footprint and sales potential of software vendors, games publishers and service providers across 140 countries around the world. In today’s uncertain business environment, the e-commerce and payment leader is looking to leverage its best technologies to offer a seamless purchase experience, helping its clients to remain flexible in their strategic approach to e-commerce. Nexway‘s teams are driving versatility, flexibility, and frictionless features to conquer new markets and expand into vertical sectors linked to customer monetization, subscriptions, and B2B sales management. Nexway also intends to continue growing thanks to its agility, expertise, and high level of the customer purchase experience. "Customer experience is a constantly moving target, changing to m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom